Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
CRNX
Stock Latest News
Company Announcements
Crinetics Pharma’s Atumelnant Study: A Promising Phase 1 Update
15m ago
CRNX
Premium
Company Announcements
Crinetics Pharma’s Paltusotine Study: A Potential Game-Changer for Carcinoid Syndrome
2h ago
CRNX
Premium
Company Announcements
Crinetics Pharma’s CRN09682 Study: A Potential Breakthrough in Tumor Treatment
2h ago
CRNX
Premium
Company Announcements
Crinetics Pharma’s Promising Extension Study on Atumelnant: A Potential Game-Changer for Adrenal Disorders
3h ago
CRNX
Premium
Company Announcements
Crinetics Pharma’s New Study on Atumelnant: A Potential Game-Changer for CAH Treatment
4h ago
CRNX
Premium
Company Announcements
Crinetics Pharma’s Promising Study on Atumelnant for Pediatric CAH
4h ago
CRNX
Premium
Company Announcements
Crinetics Pharma’s Promising Study on CRN04894 for Cushing’s Syndrome: A Potential Game-Changer?
6h ago
CRNX
Premium
Market News
3 Best Stocks to Buy Now, 10/27/2025, According to Top Analysts
11h ago
WAY
CRNX
Premium
Ratings
Promising Phase 3 Data and Strong Financial Position Justify Buy Rating for Crinetics Pharmaceuticals
3d ago
CRNX
Premium
The Fly
Crinetics to highlight neuroendocrine tumor research progress at NANETS 2025
4d ago
CRNX
Premium
Ratings
Positive Long-Term Growth Outlook for Crinetics Pharmaceuticals Amid Palsonify Approval
5d ago
CRNX
Premium
Market News
3 Must-See Stocks with Strong-Buy Ratings and a Perfect 10 Score
20d ago
PGY
CRNX
Premium
The Fly
Crinetics price target raised to $87 from $73 at Oppenheimer
28d ago
CRNX
Premium
The Fly
Crinetics price target raised to $75 from $58 at Stifel
28d ago
CRNX
Premium
The Fly
Crinetics price target raised to $77 from $65 at Morgan Stanley
29d ago
CRNX
Premium
The Fly
Trump threatens new tariffs on drugs, kitchen cabinets, trucks: Morning Buzz
1M ago
W
HD
Premium
The Fly
Crinetics rises 25.7%
1M ago
CRNX
Premium
The Fly
Crinetics rises 21.9%
1M ago
CRNX
Premium
The Fly
Crinetics price target raised to $62 from $58 at Baird
1M ago
CRNX
Premium
Ratings
Buy Rating for Crinetics Pharmaceuticals Driven by FDA Approval and Strategic Market Positioning of Palsonify
1M ago
CRNX
Premium
Company Announcements
Crinetics Pharmaceuticals Gains FDA Approval for PALSONIFY
1M ago
8K
CRNX
Premium
The Fly
Crinetics price target raised to $143 from $86 at Citizens JMP
1M ago
CRNX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.